Physician profile
Lynn M Frazier
NPI 1619918505
$106,239.30
in general payments reported to CMS, 2019-2025
30 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $24K · 2023: $14K · 2024: $24K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,025 · Food and Beverage: $7,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,518.88 |
| Travel and Lodging | $18,416.93 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,025.00 |
| Food and Beverage | $7,785.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48,534.10 | 2021-2025 | Epclusa, Livdelzi, Biktarvy |
| Intercept Pharmaceuticals, INC. | $20,449.23 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $15,187.89 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $13,143.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $5,325.68 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $1,112.54 | 2021-2025 | Stelara, Tremfya |
| Viiv Healthcare Company | $679.85 | 2022-2025 | Dovato, Cabenuva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $540.57 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $211.59 | 2022-2023 | Stelara, Remicade, Simponi Aria |
| Novo Nordisk INC | $163.36 | 2022-2025 | Wegovy |
| Mirum Pharmaceuticals, INC. | $149.96 | 2025 | Livmarli |
| Redhill Biopharma INC. | $130.12 | 2021-2023 | Talicia |
| Janssen Pharmaceuticals, INC | $123.31 | 2021 | |
| Axsome Therapeutics, INC. | $103.67 | 2024 | Auvelity |
| Aimmune Therapeutics, INC. | $43.72 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $40.15 | 2025 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $36.71 | 2022-2024 | Givlaari |
| Evoke Pharma, INC. | $30.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.07 | 2025 | Capvaxive, Pifeltro |
| Shield Therapeutics INC | $25.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $24.19 | 2025 | |
| Allergan, INC. | $21.50 | 2022 | |
| Medtronic, INC. | $17.91 | 2023 | Interstim |
| Pfizer INC. | $16.13 | 2022 | |
| Genentech USA, INC. | $15.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.03 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.91 | 2021 | |
| Celgene Corporation | $12.77 | 2023 | Zeposia |
| Boston Scientific Corporation | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.